IARS1 and ductal breast carcinoma in situ: In contrast, another report employing immunohistochemistry to evaluate GLO-1 expression in breast cancer found no significant difference between ductal carcinoma in situ and invasive tumors, with the majority of tumor samples exhibiting a GLO-1-IRS greater than 7, a value considered an appropriate cutoff for survival analysis (41).